ETFChannel.com
HALO Description — Halozyme Therapeutics Inc

Halozyme Therapeutics is a biopharma technology platform company that provides solutions to improve patient experience and outcomes. Co.'s approved product and its collaborators' approved products and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. Co. refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as its ENHANZE® drug delivery technology (ENHANZE). Co. licenses the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.

Company Name: 
Halozyme Therapeutics Inc
Website: 
www.halozyme.com
Sector: 
Biotechnology
Number of ETFs Holding HALO: 
64
Total Market Value Held by ETFs: 
$1,406,616,624.49
Total Market Capitalization: 
$7,054,000,000
% of Market Cap. Held by ETFs: 
19.94%
 ETF   HALO Weight   HALO Amount 
 IJH   0.31%   $224,376,798         
 VTI   0.02%   $219,271,108         
 VB   0.14%   $185,965,938         
 IWM   0.27%   $157,630,233         
 VBK   0.34%   $107,364,849         
 VXF   0.11%   $97,149,038         
 XBI   0.81%   $69,945,682         
 MDY   0.31%   $63,827,854         
 IWO   0.54%   $57,265,530         
 IJK   0.63%   $48,278,473         
List of all 64 ETFs holding HALO »
Quotes delayed 20 minutes

Email EnvelopeFree HALO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.44 out of 4)
53rd percentile
(ranked higher than approx. 53% of all stocks covered)

Analysts Forecast:
HALO Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding HALO | Halozyme Therapeutics Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.